DeCure for Hypophosphatemic nephrolithiasis/osteoporosis 1
DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for hypophosphatemic nephrolithiasis/osteoporosis 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypophosphatemic nephrolithiasis/osteoporosis 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypophosphatemic nephrolithiasis/osteoporosis 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of International Medical Research · 2020 · 11 citations · open access
Heterozygous mutation of <i>SLC34A1</i> in patients with hypophosphatemic kidney stones and osteoporosis: a case report
AbstractHypophosphatemic kidney stones with osteoporosis is a rare disease clinically. Mutations in the solute carrier family 34 member 1 gene ( SLC34A1), encoding NaPi-IIa, are considered to be associated with this disease. In this report, a 38-year-old Chinese woman was diagnosed with hypophosphatemic kidney stones with osteoporosis. Her clinical features were recorded, and biochemical tests and DNA sequencing were performed of the proband and her parents. Sequencing revealed that she inherited the c.1753T>C SLC34A1 mutation from her mother. This mutation in exon 13 of SLC34A1 causes a substitution of serine with proline (p. S585P) at position 585 of NaPi-IIa. This is a novel mutation that has not previously been reported, and which shows autosomal dominant inheritance. It is expected to lead to changes in protein function, and we believe that it is the cause of pathology in our patient.
Data Archiving and Networked Services (DANS) · 2019 · 0 citations · open access
Data from: Predictors of nephrolithiasis, osteoporosis and mortality in primary hyperparathyroidism
AbstractContext: Primary Hyperparathyroidism (PHPT) has a prevalence of 0.86% and is associated with increased risk of nephrolithiasis and osteoporosis. PHPT may also be associated with an increased risk of cardiovascular disease and mortality. Objective: To identify risk factors for nephrolithiasis, osteoporosis and mortality in PHPT. Design: Retrospective cohort study. Setting: University teaching hospital. Patients: PHPT presenting between 2006 – 2014 (n = 611). Main outcome measures: Assessment of nephrolithiasis, osteoporosis and mortality. Results: 13.9% of PHPT patients had nephrolithiasis. Most had already documented stone disease and only 4.7% of asymptomatic patients screened for renal stones had calculi identified, not very dissimilar to the rate in the non-PHPT population. Younger age (P < 0.001) and male gender (P = 0.003) were the only independent predictors of nephrolithiasis. 48.4% of patients with DXA data had osteoporosis (223/461). Older age (P < 0.001), lower BMI (P = 0.002) and lower creatinine (P = 0.006) were independently associated with a diagnosis of osteoporosis. Higher PTH was independently associated with lower Z-score at the hip (P = 0.009), but otherwise calcium and PTH were not associated with lower Z-score. Mortality in PHPT was associated with older age (P < 0.008), social deprivation (P = 0.028) and adjusted calcium (P = 0.009) but not independently with PTH at diagnosis. Conclusions: Screening for nephrolithiasis has a low yield, particularly in lower risk patients. Osteoporosis is only minimally associated with biochemical indices of PHPT. Mortality is associated with higher calcium (and possibly vitamin D deficiency) but not PTH.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
